Cargando…

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting

BACKGROUND: Tildrakizumab is a high-affinity, humanized IgG1κ monoclonal antibody targeting the p19 subunit of IL-23, which is a key regulatory cytokine in psoriasis. Based on evidence from clinical trials, tildrakizumab is approved for the treatment of moderate-to-severe plaque psoriasis in patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burlando, Martina, Castelli, Riccardo, Cozzani, Emanuele, Parodi, Aurora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioExcel Publishing Ltd 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152773/ https://www.ncbi.nlm.nih.gov/pubmed/34104197 http://dx.doi.org/10.7573/dic.2021-2-6

Ejemplares similares

Erratum: Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
Publicado: (2021)

Tildrakizumab in moderate‐to‐severe plaque psoriasis: A multicenter, retrospective, real‐life study
por: Caldarola, Giacomo, et al.
Publicado: (2022)

Bulky Condyloma Acuminata following Ustekinumab Treatment for Plaque Psoriasis: A Case Report
por: Burlando, Martina, et al.
Publicado: (2021)

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
por: Beck, Kristen M, et al.
Publicado: (2018)

Erythema multiforme after initiation of anti interleukin-12/23 (ustekinumab) treatment for plaque psoriasis
por: Burlando, Martina, et al.
Publicado: (2020)

Severe Generalized Pustular Psoriasis Successfully Treated with Ixekizumab: A Case Report
por: Burlando, Martina, et al.
Publicado: (2022)

Psoriasis flares after COVID-19 vaccination: adherence to biologic therapy reduces psoriasis exacerbations: a case-control study
por: Burlando, Martina, et al.
Publicado: (2023)

Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
por: Näslund-Koch, Charlotte, et al.
Publicado: (2020)

Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis)
por: Narcisi, Alessandra, et al.
Publicado: (2022)

Psoriasis, Vitiligo, and Biologic Therapy: Case Report and Narrative Review
por: Burlando, Martina, et al.
Publicado: (2021)

“De Novo” Psoriasis and Relapse of Psoriasis Induced by Dupilumab: Three New Cases and Review of the Literature
por: Trave, Ilaria, et al.
Publicado: (2023)

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
por: Ruggiero, Angelo, et al.
Publicado: (2023)

A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis
por: Becher, Gabrielle, et al.
Publicado: (2022)

A purplish plaque and multiple nodules on the arm
por: Burlando, Martina, et al.
Publicado: (2022)

Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients
por: Burlando, Martina, et al.
Publicado: (2022)

Dimethyl fumarate titration for the systemic treatment of moderate-to-severe plaque psoriasis
por: Malara, Giovanna, et al.
Publicado: (2021)

Guselkumab‐associated bullous pemphigoid in a psoriasis patient: A case report and review of the literature
por: Burlando, Martina, et al.
Publicado: (2021)

The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis
por: Carrico, Justin, et al.
Publicado: (2020)

Erythrodermic psoriasis improved by Tildrakizumab
por: Trevisan, Giampaolo, et al.
Publicado: (2022)

Tildrakizumab in the treatment of psoriasis – literature review
por: Banaszczyk, Katarzyna
Publicado: (2019)

Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study
por: GNESOTTO, Laura, et al.
Publicado: (2023)

The HLA-Cw6 Dilemma: Is It Really an Outcome Predictor in Psoriasis Patients under Biologic Therapy? A Monocentric Retrospective Analysis
por: Burlando, Martina, et al.
Publicado: (2020)

Comedonal variant of chronic cutaneous lupus erythematosus causing mutilation of the earlobe
por: Cozzani, Emanuele, et al.
Publicado: (2020)

Acute urticarial rash after COVID-19 vaccination containing Polysorbate 80
por: Burlando, Martina, et al.
Publicado: (2021)

The 30th birthday of chronic ulcerative stomatitis: A systematic review
por: Herzum, Astrid, et al.
Publicado: (2021)

Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy
por: Pithadia, Deeti J., et al.
Publicado: (2019)

Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1)
por: Igarashi, Atsuyuki, et al.
Publicado: (2021)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Cutaneous reactions to COVID‐19 vaccine at the dermatology primary care
por: Burlando, Martina, et al.
Publicado: (2021)

Considerations on inhibition of IL‐23 in psoriatic women of childbearing potential
por: Russo, Roberto, et al.
Publicado: (2021)

Results of COVID-19 screening in a dermatologic clinic in Northern Italy
por: BURLANDO, MARTINA, et al.
Publicado: (2023)

Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study
por: Menter, M.A., et al.
Publicado: (2020)

Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: DIMESKIN-2, a Multicentre Single-Arm Phase IIIb Study
por: Pellacani, Giovanni, et al.
Publicado: (2022)

Real‐world effectiveness and safety of tildrakizumab in long‐term treatment of plaque psoriasis: Results from the non‐interventional, prospective, multicentre study TILOT
por: Tsianakas, Athanasios, et al.
Publicado: (2022)

Reticular Erythematous Mucinosis: Exclusive Involvement of the Axillary Region
por: Burlando, Martina, et al.
Publicado: (2021)

Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?
por: Megna, Matteo, et al.
Publicado: (2021)

Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
por: Galluzzo, Marco, et al.
Publicado: (2020)

A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study
por: Zagni, Emanuela, et al.
Publicado: (2021)

A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients
por: Campione, Elena, et al.
Publicado: (2023)

Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials
por: Blauvelt, A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gjdt9d6cajlbp72akqbenpe483